This classification deeply influences the prognosis: indeed, hormone receptor positive BC generally has a more favorable outcome, whereas triple-negative BC is more aggressive, and few therapeutic alternatives exist to treat it [49]. This evidence concerns the gene NR4A1 and breast cancer.